COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
13 hedge funds and large institutions have $130K invested in COSCIENS Biopharma Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 6 closing their positions.
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
30% more funds holding
Funds holding: 10 → 13 (+3)
23% more capital invested
Capital invested by funds: $106K → $130K (+$24K)
0.68% more ownership
Funds ownership: 0.25% → 0.93% (+0.68%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$104K |
| 2 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$37.4K |
| 3 |
TWC
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
+$28.3K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$19.1K |
| 5 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$18K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$33.9K |
| 2 |
Morgan Stanley
New York
|
-$30.8K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$23.8K |
| 4 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
-$8.76K |
| 5 |
JP Morgan Chase
New York
|
-$1.3K |
CSCI Hedge Fund Activity: Q2 2024 in Review
13 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q2 2024, worth a combined $130K — up 23% from $106K a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CSCI positions and 6 closed out — a net gain of 3 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $104K. The largest seller was Citadel Advisors, exiting entirely with an estimated $33.9K sold.
- 13 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q2 2024, up from 10 in Q1 2024.
- Funds reported $130K of COSCIENS Biopharma Inc. Common Stock stock for Q2 2024, up 23% quarter-over-quarter.
- 9 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q2 2024 and 6 closed out, a net change of +3 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q2 2024 was Susquehanna International Group, an estimated $104K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q2 2024 was Citadel Advisors, an estimated $33.9K sold.
Based on aggregated 13F filings for Q2 2024.